|
|
|
| Meta-analysisof effect comparison of Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of schizophrenia |
| LI Yan1 BA Wen-qiang2 YUAN Ye-feng3▲ |
1.Department of Psychiatry,Ji′an Third People′s Hospital,Jiangxi Province,Ji′an 343000,China;
2.Department of Pharmacy,Ji′an Central People′s Hospital,Jiangxi Province,Ji′an 343000,China;
3.Department of Psychosomatic Medicine,the First Affiliated Hospital of Nanchang University,Jiangxi Province,Nanchang 330000,China |
|
|
|
|
Abstract Objective To compare the effect and adverse reactions of Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of schizophrenia by Meta-analysis.Methods Randomized controlled trials(RCTs)related to the Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of patients with schizophrenia were searched in China National Knowledge Infrastructure,Wanfang,Weipu Database,Chinese Biomedical Literature Service System,PubMed,Embase,Cochrane Library databases.Search time was from the establishment of the database to October 2019.Meta-analysis was carried out with RevMan 5.3 software.Results Finally,a total of 22 RCTs literatures were included.Meta-analysis showed that compared with the Aripiprazole group,the reduction of total score of positive and negative symptoms scale (PANSS)in the Paliperidone Sustained-release Tablets group was better after 2 and 4 weeksof treatment,and the differences were statistically significant(after 2 weeks of treatment：MD=-8.43,95%CI[-14.61,-2.26],P=0.007;after 4 weeks of treatment：MD=-5.23,95%CI[-9.57,-0.89],P=0.02).After 8 weeks of treatment,there were no significant differences in the PANSSscore(MD=-5.47,95%CI[-11.31,-0.38],P=0.07),positive symptoms score(MD=-2.49,95%CI[-7.33,2.34],P=0.31),and the general psychotic symptoms score(MD=-1.43,95%CI[-5.99,3.12],P=0.54)between the two groups.Compared with Aripiprazole group,the reduction of negative symptoms score of Paliperidone Sustained-release Tablets group was better,and the difference was statistically significant(MD=-1.18,95%CI[-2.10,-0.26],P=0.01).The prolactin level in the Paliperidone Sustained-release Tablets group was higher than that in the Aripiprazole group,and the difference was statistically significant(MD=31.39,95%CI[13.62,49.15],P=0.0005).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion Paliperidone Sustained-release Tablets are as effective as Aripiprazole in the treatment of schizophrenia.However,it has faster onset and much better effect for the negative symptoms.The incidence of adverse reactions between the two drugs is similar,but Paliperidone Sustained-release Tablets can increase the serum prolactin level of patients.
|
|
Received: 06 March 2020
|
|
|
|
| [11] |
路广义.帕利哌酮缓释片和阿立哌唑治疗精神病的临床疗效及并发症分析[J].中国保健营养，2015，25（15）：231-232.
|
| [12] |
陈勇.帕利哌酮缓释片与阿立哌唑口崩片治疗精神分裂症对照研究[J].医学信息，2015，28（13）：21.
|
| [1] |
沈渔邨.精神病学[M].5版.北京：人民卫生出版社，2009，526-532.
|
| [2] |
管丽丽，杜立哲，马弘.精神分裂症的疾病负担（综述）[J].中国心理卫生杂志，2012，26（12）：913-919.
|
| [3] |
司天梅，黄继忠，李晓白，等.帕利哌酮缓释片临床用药指导意 见（第二版）[J].中国新药杂 志，2016，25（9）：1029-1035.
|
| [4] |
World Health Organization.International statistical classification of diseases and related health problems[M].World Health Organization，2004.
|
| [7] |
李佟，苏旭江.精神分裂症患者经盐酸帕利哌酮治疗的临床效果观察[C].//中华医学会与中国医药教育协会.2015临床急重症经验交流第二次高峰论坛，2015，1-2.
|
| [8] |
李建华，兰光华，那万秋，等.帕利哌酮和阿立哌唑治疗精神分裂症的对照研究[J].齐齐哈尔医学院学报，2011，32（3）：351-353.
|
| [9] |
刘明秋.帕利哌酮缓释片和阿立哌唑治疗精神病的临床疗效及并发症[J].中国实用神经疾病杂志，2014，17（21）：28-30.
|
| [10] |
刘卫平.帕利哌酮缓释片和阿立哌唑治疗精神病的临床疗效及并发症[J].中国现代药物应用，2015，9（11）：127-128.
|
| [5] |
American Psychiatric Association.DSM-IV-TR：Diagnostic and Statistical Manual of Mental Disorders，4th edn，text revision[J].Washington，DC：American Psychiatric Association，2000：739-799.
|
| [6] |
Jadad AR，Moore RA，Carroll D，et al.Assessing the quality of reports of randomized clinical trials：is blinding necessary?[J].Control Clin Trials，1996，17（1）：1-12.
|
| [13] |
路广义，徐丽，刘秋丽.帕利哌酮缓释片与阿立哌唑口腔崩解片治疗精神分裂症的对照研究[J].中国伤残医学，2015，23（17）：28-30.
|
| [14] |
麦以成，徐彩霞，罗澍韩.帕利哌酮缓释片与阿立哌唑治疗精神分裂症对照研究[J].临床心身疾病杂志，2010，16（4）：313-315.
|
| [15] |
杨国平，吴越，顾君，等.帕利哌酮缓释片与阿立哌唑治疗首发精神分裂症对照研究[J].中国健康心理学杂志，2013，21（2）：185-186.
|
| [16] |
李建华，苏伟，任丽华.帕利哌酮与阿立哌唑对首发精神分裂症代谢相关指标的影响[J].浙江中西医结合杂志，2016，26（8）：724-726.
|
| [17] |
林文.帕利哌酮与阿立哌唑治疗精神分裂症的疗效观察[J].中国实用神经疾病杂志，2012，15（24）：67-69.
|
| [18] |
阳前军，刘冰，丁凡.帕利哌酮与阿立哌唑治疗精神分裂症的临床疗效[J].中国实用神经疾病杂志，2015，18（12）：47-48.
|
| [19] |
周怀忠，王朔，李毅，等.帕利哌酮与阿立哌唑治疗男性精神分裂症患者疗效及对性功能的影响对照[J].中国医院药学杂志，2013，33（4）：308-311.
|
| [20] |
高宏强，尤加永，顾广善，等.帕利哌酮与阿立哌唑治疗女性首发精神分裂症疗效、安全性及其对个人和社会功能影响的研究[J].海峡药学，2016，28（6）：96-99.
|
| [21] |
谢琴，汤珺，周蕾，等.帕利哌酮与阿立哌唑治疗青少年首发精神分裂症的临床对照研究[J].中国新药与临床杂志，2013，32（1）：51-55.
|
| [22] |
郭占锐，邓江，张晓，等.帕利哌酮治疗精神分裂症临床研究[J].河南科技大学学报（医学版），2014，32（2）：115-116.
|
| [23] |
桑玉军.帕利哌酮缓释片和阿立哌唑对精神病的治疗价值对照[J].中国保健营养，2015，25（12）：29.
|
| [24] |
冯婉霞，陈婉珉，莫翠英，等.帕利哌酮、阿立哌唑和利培酮对首发精神分裂症患者的临床疗效观察[J].广西医科大学学报，2015，32（4）：623-625.
|
| [25] |
李彬.帕利哌酮和阿立哌唑治疗精神分裂症疗效对比分析[J].医药前沿，2014，（5）：147-148.
|
| [26] |
任智勇，崔莉莉，赵轶，等.帕利哌酮阿立哌唑对首发精神分裂症患者的临床疗效观察[J].中国药物与临床，2019，19（4）：635-637.
|
| [27] |
汪毅，甘明远，刘华清，等.帕利哌酮缓释片与阿立哌唑治疗青少年首发精神分裂症的疗效和催乳素变化[J].中国心理卫生杂志，2019，33（8）：592-597.
|
| [28] |
Adam J，Rosanne L，Isaac N，et al.Efficacy and safety of paliperidone extended release in adolescents with schizophrenia：A Randomized，Double-Blind Study[J].JAm Acad Child Adolesc Psychiatry，2015，54（2）：126-137.
|
| [29] |
Fowler JA，Bettinger TL，Argo TR.Paliperidone extendedrelease tablets for the acute and maintenance treatment of schizophrenia[J].Clin Ther，2008，30（2）：231-248.
|
| [30] |
Zhang JP，Robinson DG，Gallego JA，et al.Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis[J].Schizophr Bull，2015，41（6）：1248-1255.
|
| [31] |
Bartolomeis A，Tomasetti C，Iasevoli F.Update on the mechanism of action of aripiprazole：translational insights into antipsychotic strategies beyond dopamine receptor antagonism[J].CNSDrugs，2015，29（9）：773-799.
|
| [32] |
Melnik T，Soares BG，Puga ME，et al.Efficacy and safety of atypical antipsychotic drugs（quetiapine，resperidone，aripiprazole and paliperidone）compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia：overview of systematic reviews[J].Sao Paulo Med J，2010，128（3）：141-166.
|
| [33] |
Canuso CM，Youss ef EA，Bossie CA，et al.Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone[J].Int Clin Psychopharmacol，2008，23（4）：209-215.
|
| [34] |
Qiao Y，Yang F，Li C，et al.Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone[J].Psychiatry Res，2016，237：83-89.
|
| [35] |
Petty RG.Prolactin and antipsychotic medications：mechanism of action[J].Schizophrenia Res，1999，35 Suppl：S67-S73.
|
|
|
|
